Skip to content

Rapport Therapeutics, Inc. RAPP Noncash Or Part Noncash Acquisition Fixed Assets Acquired1

Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 at other companies

Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$0-100%

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$24.2M+10.7%
Net income-$19.9M+17.5%
EPS (diluted)-$0.42+38.2%

Balance sheet

See full
Cash & equivalents$78.1M+35.5%
Total debt$10.8M+37.8%
Total equity$471.5M+65.0%
Total assets$497.6M+64.7%

Cash flow

See full
Operating cash flow-$13.1M+35.5%
CapEx$86.0K-70.4%
Free cash flow-$13.1M+36.0%

Valuation

See full
Market cap$1.86B+309%
Enterprise value$1.79B+352%

Returns & leverage

See full
Return on equity-28.3%
Debt / equity0.0×
Current ratio27.1×-3.9×

Where this comes from

Reported directly by Rapport Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1.

The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapport Therapeutics, Inc.'s noncash or part noncash acquisition fixed assets acquired1.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rapport Therapeutics, Inc.'s noncash or part noncash acquisition fixed assets acquired1?
Rapport Therapeutics, Inc. (RAPP) reported noncash or part noncash acquisition fixed assets acquired1 of $49K in Q1 2026.
What does noncash or part noncash acquisition fixed assets acquired1 mean?
Captures the value of fixed assets acquired through non-cash transactions, such as financing arrangements or asset exchanges. This metric ensures that significant capital investments are accounted for even when they do not involve an immediate cash outflow. It provides a more complete picture of the company's investment in property, plant, and equipment.